TDMS Study 05188-06 Pathology Tables
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
Facility: Battelle Columbus Laboratory
Chemical CAS #: 1300-72-7
Lock Date: 07/28/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 7 10 9 8
Moribund Sacrifice 12 7 9 6
Survivors
Terminal Sacrifice 31 32 32 36
Missing 1
Animals Examined Microscopically 50 49 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (49) (17) (18) (50)
Leiomyosarcoma, Metastatic, Intestine Small,
Jejunum 1 (6%)
Intestine Large, Cecum (50) (16) (18) (50)
Leiomyosarcoma 1 (6%)
Intestine Small, Jejunum (49) (16) (18) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Leiomyosarcoma 1 (6%)
Liver (50) (49) (50) (50)
Hemangioma 2 (4%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 9 (18%) 10 (20%) 7 (14%) 8 (16%)
Hepatocellular Carcinoma, Multiple 1 (2%) 3 (6%) 2 (4%)
Hepatocellular Adenoma 10 (20%) 8 (16%) 14 (28%) 19 (38%)
Hepatocellular Adenoma, Multiple 8 (16%) 9 (18%) 4 (8%) 9 (18%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 3 (6%) 2 (4%) 2 (4%) 2 (4%)
Leiomyosarcoma, Metastatic, Intestine Small,
Jejunum 1 (2%)
Mesentery (7) (6) (5) (12)
Fibrosarcoma, Metastatic, Skin 1 (8%)
Hemangioma 1 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (14%) 1 (20%) 2 (17%)
Histiocytic Sarcoma 1 (14%) 1 (17%) 1 (20%)
Leiomyosarcoma, Metastatic, Intestine Small,
Jejunum 1 (20%)
Pancreas (50) (17) (18) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (6%)
Histiocytic Sarcoma 1 (2%) 1 (6%) 1 (6%)
Leiomyosarcoma, Metastatic, Intestine Small,
Jejunum 1 (6%)
Page 2
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Salivary Glands (50) (17) (18) (50)
Stomach, Forestomach (50) (17) (18) (50)
Squamous Cell Papilloma 2 (12%)
Stomach, Glandular (50) (17) (18) (50)
Carcinoma 1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50) (17) (18) (50)
Aorta, Hepatocholangiocarcinoma, Metastatic,
Liver 1 (6%)
Heart (50) (17) (18) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (6%)
Histiocytic Sarcoma 2 (4%) 1 (6%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (17) (18) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%)
Capsule, Adenoma 1 (2%) 1 (2%)
Adrenal Medulla (50) (17) (18) (48)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (17) (18) (50)
Adenoma 1 (2%) 1 (6%)
Carcinoma 1 (2%)
Pituitary Gland (50) (17) (18) (49)
Meningioma Malignant, Metastatic, Brain 1 (6%)
Pars Distalis, Adenoma 7 (14%) 3 (18%) 1 (6%) 5 (10%)
Pars Intermedia, Adenoma 1 (2%) 2 (4%)
Pars Intermedia, Carcinoma 1 (2%)
Thyroid Gland (50) (48) (50) (50)
Follicular Cell, Adenoma 1 (2%) 5 (10%) 1 (2%) 6 (12%)
Follicular Cell, Adenoma, Multiple 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (49) (15) (15) (46)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Ovary (50) (17) (18) (49)
Cystadenoma 1 (6%) 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangioma 1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%)
Histiocytic Sarcoma 1 (2%) 1 (6%) 1 (6%) 1 (2%)
Teratoma Benign 1 (2%)
Uterus (50) (17) (18) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (12%) 1 (2%)
Leiomyosarcoma, Metastatic, Intestine Small,
Jejunum 1 (6%)
Polyp Stromal 3 (6%) 1 (6%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (17) (18) (50)
Histiocytic Sarcoma 1 (2%) 2 (12%)
Lymph Node (7) (3) (6) (6)
Bronchial, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (17%)
Inguinal, Histiocytic Sarcoma 1 (17%)
Lumbar, Histiocytic Sarcoma 2 (67%) 2 (33%)
Mediastinal, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (14%) 1 (17%) 1 (17%)
Mediastinal, Histiocytic Sarcoma 1 (14%) 1 (33%) 1 (17%)
Pancreatic, Histiocytic Sarcoma 1 (17%)
Renal, Hepatocholangiocarcinoma, Metastatic,
Liver 1 (17%)
Renal, Histiocytic Sarcoma 1 (17%) 1 (17%)
Thoracic, Fibrosarcoma, Metastatic, Skin 1 (14%)
Lymph Node, Mandibular (49) (15) (15) (48)
Carcinoma, Metastatic, Harderian Gland 1 (7%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Lymph Node, Mesenteric (48) (17) (17) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) 2 (4%)
Histiocytic Sarcoma 2 (4%) 2 (12%) 1 (6%) 2 (4%)
Leiomyosarcoma, Metastatic, Intestine Small,
Jejunum 1 (6%)
Spleen (50) (17) (18) (50)
Hemangiosarcoma 1 (6%) 2 (4%)
Histiocytic Sarcoma 3 (6%) 1 (6%) 1 (2%)
Page 4
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Thymus (38) (16) (16) (44)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) 2 (5%)
Histiocytic Sarcoma 1 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (17) (16) (50)
Carcinoma 1 (2%)
Skin (50) (49) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Fibrosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (17) (18) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (3)
Fibrosarcoma, Metastatic, Skin 1 (33%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%) 2 (67%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (17) (18) (50)
Carcinoma, Metastatic, Harderian Gland 1 (6%)
Histiocytic Sarcoma 1 (2%)
Meningioma Malignant 1 (6%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (18) (18) (50)
Alveolar/Bronchiolar Adenoma 4 (8%) 1 (6%) 2 (11%) 6 (12%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (6%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 2 (11%) 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 2 (11%) 1 (6%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (6%) 2 (4%)
Histiocytic Sarcoma 3 (6%) 1 (6%) 2 (4%)
Leiomyosarcoma, Metastatic, Intestine Small,
Jejunum 1 (6%)
Page 5
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Leiomyosarcoma, Metastatic, Intestine Large,
Cecum 1 (6%)
Squamous Cell Carcinoma, Metastatic, Urinary
Bladder 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (6%)
Nose (50) (17) (18) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (2)
Carcinoma, Metastatic, Harderian Gland 1 (50%)
Harderian Gland (5) (2) (1) (3)
Adenoma 2 (40%) 1 (33%)
Carcinoma 1 (20%) 2 (100%) 1 (100%) 2 (67%)
Bilateral, Adenoma 1 (20%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (17) (18) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 3 (6%) 2 (12%)
Urinary Bladder (50) (17) (18) (50)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(49) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 2 (4%) 2 (4%) 2 (4%)
Lymphoma Malignant 8 (16%) 3 (6%) 3 (6%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 45 34 31 44
Total Primary Neoplasms 71 54 44 82
Total Animals with Benign Neoplasms 29 22 20 35
Total Benign Neoplasms 43 30 24 52
Total Animals with Malignant Neoplasms 25 22 18 26
Total Malignant Neoplasms 28 24 20 30
Total Animals with Metastatic Neoplasms 5 5 5 8
Total Metastatic Neoplasm 9 8 24 25
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 11 10 3 9
Moribund Sacrifice 7 3 8 6
Survivors
Terminal Sacrifice 32 37 39 35
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (50) (12) (11) (50)
Liver (50) (50) (50) (50)
Hemangioma 2 (4%) 1 (2%)
Hemangiosarcoma 2 (4%) 2 (4%) 1 (2%)
Hemangiosarcoma, Multiple 3 (6%) 3 (6%) 2 (4%) 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%) 1 (2%) 3 (6%)
Hepatoblastoma 4 (8%) 2 (4%)
Hepatocellular Carcinoma 21 (42%) 17 (34%) 12 (24%) 15 (30%)
Hepatocellular Carcinoma, Multiple 14 (28%) 14 (28%) 10 (20%) 11 (22%)
Hepatocellular Adenoma 15 (30%) 21 (42%) 14 (28%) 13 (26%)
Hepatocellular Adenoma, Multiple 22 (44%) 11 (22%) 7 (14%) 16 (32%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mesentery (5) (4)
Hemangiosarcoma, Metastatic, Spleen 1 (20%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (20%)
Liposarcoma, Multiple 1 (25%)
Pancreas (50) (13) (11) (50)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Salivary Glands (50) (13) (11) (50)
Stomach, Forestomach (50) (13) (11) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (50) (13) (11) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (13) (11) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (8%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Page 8
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - cont
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (12) (11) (50)
Adrenal Medulla (50) (12) (11) (50)
Pheochromocytoma Benign 2 (4%)
Pituitary Gland (49) (12) (10) (50)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (50) (13) (11) (50)
Follicular Cell, Adenoma 2 (4%) 1 (9%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (13) (11) (50)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Prostate (50) (13) (11) (50)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Seminal Vesicle (50) (13) (11) (50)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (13) (11) (50)
Hemangiosarcoma 1 (9%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (9%)
Lymph Node (3) (2) (2) (3)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (50%)
Mediastinal, Hemangiosarcoma, Metastatic,
Liver 1 (33%)
Mediastinal, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (33%)
Mediastinal, Histiocytic Sarcoma 1 (50%)
Lymph Node, Mandibular (43) (7) (8) (42)
Lymph Node, Mesenteric (50) (9) (10) (47)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Spleen (50) (13) (12) (49)
Hemangiosarcoma 2 (4%) 1 (8%) 1 (8%) 3 (6%)
Page 9
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Hemangiosarcoma, Metastatic, Bone Marrow 1 (8%)
Liposarcoma, Metastatic, Mesentery 1 (2%)
Thymus (37) (11) (6) (34)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (9%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (9%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Hemangioma 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Skin, Site of
Application, Histiocytic Sarcoma 2 (4%)
Subcutaneous Tissue, Skin, Site of
Application, Lymphoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (3)
Hepatocellular Carcinoma, Metastatic, Liver 1 (33%)
Liposarcoma, Metastatic, Mesentery 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (13) (11) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (16) (15) (50)
Alveolar/Bronchiolar Adenoma 12 (24%) 4 (25%) 2 (13%) 7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (6%) 1 (7%) 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatoblastoma, Metastatic, Liver 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 12 (24%) 5 (31%) 7 (47%) 11 (22%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (6%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Page 10
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Metastatic, Lung 1 (6%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (1) (3)
Adenoma 1 (50%) 1 (100%) 1 (33%)
Carcinoma 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (13) (11) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (8%) 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%)
Lymphoma Malignant 5 (10%) 4 (8%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96
Route: SKIN APPLICATION Time: 05:02:39
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 182 364 727
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 41 36 47
Total Primary Neoplasms 108 78 60 90
Total Animals with Benign Neoplasms 43 33 24 37
Total Benign Neoplasms 58 36 26 46
Total Animals with Malignant Neoplasms 39 33 28 33
Total Malignant Neoplasms 50 42 34 44
Total Animals with Metastatic Neoplasms 15 6 10 16
Total Metastatic Neoplasm 21 11 11 26
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------